Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Weighted Average and Diluted) (2020 - 2025)

Adma Biologics (ADMA) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with $0.2 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 55.56% year-over-year to $0.2, compared with a TTM value of $0.6 through Dec 2025, down 25.93%, and an annual FY2025 reading of $0.6, down 25.93% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.2 for Q4 2025 at Adma Biologics, up from $0.15 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.45 in Q4 2024 and bottomed at -$0.16 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.02, with a median of -$0.03 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 1400.0% in 2024, then plummeted 55.56% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.07 in 2021, then grew by 14.29% to -$0.06 in 2022, then tumbled by 33.33% to -$0.08 in 2023, then skyrocketed by 662.5% to $0.45 in 2024, then tumbled by 55.56% to $0.2 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ADMA at $0.2 in Q4 2025, $0.15 in Q3 2025, and $0.14 in Q2 2025.